University Medical Center Hamburg, Department of Pediatric Hematology and Oncology, Hamburg, Germany.
Adv Exp Med Biol. 2024;1448:9-19. doi: 10.1007/978-3-031-59815-9_2.
Hemophagocytic lymphohistiocytosis (HLH) is a severe cytokine storm syndrome (CSS), which until the turn of the century, was barely known but is now receiving increased attention. The history of HLH dates back to 1939 when it was first described in adults, to be followed in 1952 by the first description of its primary, familial form in children. Secondary forms of HLH are far more frequent and occur with infections, malignancies, metabolic diseases, iatrogenic immune suppression, and autoinflammatory/autoimmune diseases. Identification of the genetic defects leading to the defective function of natural killer (NK) cells and cytotoxic T cells as well as the corresponding mouse models have revolutionized our understanding of HLH and of immune function. Diagnosis relies on clinical and laboratory criteria; functional and genetic tests can help separate primary from secondary forms. Treatment with immunochemotherapy and hematopoietic stem cell transplantation has considerably improved survival in children with primary HLH, a formerly uniformly fatal disease.
噬血细胞性淋巴组织细胞增生症(HLH)是一种严重的细胞因子风暴综合征(CSS),在本世纪初之前,这种疾病鲜为人知,但现在越来越受到关注。HLH 的历史可以追溯到 1939 年,当时首次在成人中描述,随后在 1952 年首次在儿童中描述了其原发性、家族性形式。继发性 HLH 更为常见,与感染、恶性肿瘤、代谢疾病、医源性免疫抑制和自身炎症/自身免疫性疾病有关。导致自然杀伤(NK)细胞和细胞毒性 T 细胞功能缺陷的遗传缺陷以及相应的小鼠模型的发现,彻底改变了我们对 HLH 和免疫功能的认识。诊断依赖于临床和实验室标准;功能和遗传测试有助于区分原发性和继发性 HLH。免疫化学治疗和造血干细胞移植的治疗极大地提高了原发性 HLH 患儿的生存率,这种疾病以前是一种致命的疾病。